

# Margarida M Castel-Branco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5522564/publications.pdf>

Version: 2024-02-01

34  
papers

1,055  
citations

687220

13  
h-index

434063

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prescription trends at the end of life in a palliative care unit: observational study. <i>BMC Palliative Care</i> , 2022, 21, 65.	0.8	9
2	Evaluation of Cardiovascular Pharmacotherapy Guideline Adherence and Risk Factor Control in Portuguese Community Pharmacy Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6170.	1.2	0
3	Association between anticholinergic burden and anticholinergic adverse outcomes in the elderly: Pharmacological basis of their predictive value for adverse outcomes. <i>Pharmacological Research</i> , 2021, 163, 105306.	3.1	10
4	Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 128-136.	1.0	10
5	Implications of a defined daily dose fixed database for drug utilization research studies: The case of statins in Portugal. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3542-3549.	1.1	3
6	Feasibility of cardiovascular risk screening in Portuguese community pharmacies. <i>Pharmacy Practice</i> , 2021, 19, 2255.	0.8	5
7	Evaluation of a sample of Portuguese hypertensive patients' knowledge about hypertension and its influence on their beliefs and adherence to therapy. <i>Revista Portuguesa De Cardiologia</i> , 2021, .	0.2	1
8	Contribution of Different Patient Information Sources to Create the Best Possible Medication History. <i>Acta Medica Portuguesa</i> , 2020, 33, 384.	0.2	4
9	Patients' clinical information requirements to apply the STOPP/START criteria. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1562-1569.	1.0	11
10	Consequences of ignoring patient diagnoses when using the 2015 Updated Beers Criteria. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 751-756.	1.0	4
11	Cross-cultural adaptation and validation of a European Portuguese version of the 8-item Morisky medication adherence scale. <i>Revista Portuguesa De Cardiologia</i> , 2018, 37, 297-303.	0.2	13
12	Response to the letter entitled: Developing an adherence in hypertension questionnaire short version, <sc>MUAH</sc>: Statistical and methodological issues. <i>Journal of Clinical Hypertension</i> , 2018, 20, 817-818.	1.0	0
13	Developing an adherence in hypertension questionnaire short version: <sc>MUAH</sc>. <i>Journal of Clinical Hypertension</i> , 2018, 20, 118-124.	1.0	14
14	A case study of polypharmacy management in nine European countries: Implications for change management and implementation. <i>PLoS ONE</i> , 2018, 13, e0195232.	1.1	42
15	Influence of the mode of administration on the results of medication adherence questionnaires. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 1252-1257.	0.9	7
16	Cross-cultural adaptation of Hypertension Knowledge Test into European Portuguese. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2017, 53, .	1.2	0
17	Identification of inhaler technique errors with a routine procedure in Portuguese community pharmacy. <i>Pharmacy Practice</i> , 2017, 15, 1072-1072.	0.8	15
18	Gastroprotective effect of <i>Cymbopogon citratus</i> infusion on acute ethanol-induced gastric lesions in rats. <i>Journal of Ethnopharmacology</i> , 2015, 173, 134-138.	2.0	22

#	ARTICLE	IF	CITATIONS
19	Evaluation of Anti-inflammatory and Analgesic Activities of Cymbopogon citratus In vivo-Polyphenols Contribution. Research Journal of Medicinal Plant, 2015, 9, 1-13.	0.3	18
20	Assessing the impact of multi-compartment compliance aids on clinical outcomes in the elderly: a pilot study. International Journal of Clinical Pharmacy, 2014, 36, 98-104.	1.0	10
21	Hepatic and renal toxicities of indomethacin acid, salt form and complexed forms with hydroxypropyl- $\beta$ -cyclodextrin on Wistar rats after oral administration. Fundamental and Clinical Pharmacology, 2011, 25, 599-607.	1.0	7
22	The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 101.	0.8	144
23	Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropyl- $\beta$ -cyclodextrin on Wistar rats: histopathologic analysis. Fundamental and Clinical Pharmacology, 2009, 23, 747-755.	1.0	6
24	Stereoselective disposition of <i>S</i> - and <i>R</i> -licarbazepine in mice. Chirality, 2008, 20, 796-804.	1.3	18
25	Disposition of eslicarbazepine acetate in the mouse after oral administration. Fundamental and Clinical Pharmacology, 2008, 22, 529-536.	1.0	12
26	Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomedical Chromatography, 2007, 21, 1127-1134.	0.8	32
27	Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, <i>S</i> -licarbazepine, <i>R</i> -licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. Analytica Chimica Acta, 2007, 596, 132-140.	2.6	29
28	Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundamental and Clinical Pharmacology, 2005, 19, 669-675.	1.0	30
29	Neuropharmacokinetic characterization of lamotrigine after its acute administration to rats. Methods and Findings in Experimental and Clinical Pharmacology, 2005, 27, 539.	0.8	6
30	Lamotrigine kidney distribution in male rats following a single intraperitoneal dose. Fundamental and Clinical Pharmacology, 2004, 18, 51-55.	1.0	3
31	Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. European Journal of Pharmacology, 2003, 482, 163-168.	1.7	30
32	Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 774, 215-222.	1.2	478
33	Influence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in rats. Fundamental and Clinical Pharmacology, 2002, 16, 331-336.	1.0	14
34	Lamotrigine analysis in blood and brain by high-performance liquid chromatography. Biomedical Applications, 2001, 755, 119-127.	1.7	48